384 related articles for article (PubMed ID: 11168932)
1. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
Islam M; Burke JF; McGowan TA; Zhu Y; Dunn SR; McCue P; Kanalas J; Sharma K
Kidney Int; 2001 Feb; 59(2):498-506. PubMed ID: 11168932
[TBL] [Abstract][Full Text] [Related]
2. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
Shihab FS; Yi H; Bennett WM; Andoh TF
Kidney Int; 2000 Sep; 58(3):1174-85. PubMed ID: 10972680
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Sun QL; Li M; Rui HL; Chen YP
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
[TBL] [Abstract][Full Text] [Related]
5. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Ma LJ; Jha S; Ling H; Pozzi A; Ledbetter S; Fogo AB
Kidney Int; 2004 Jan; 65(1):106-15. PubMed ID: 14675041
[TBL] [Abstract][Full Text] [Related]
6. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Bennett WM
Am J Kidney Dis; 1997 Jul; 30(1):71-81. PubMed ID: 9214404
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of tea polyphenols on transforming growth factor-beta1 expression in rat with cyclosporine A-induced chronic nephrotoxicity.
Shi SH; Zheng SS; Jia CK; Zhu YF; Xie HY
Acta Pharmacol Sin; 2004 Jan; 25(1):98-103. PubMed ID: 14704129
[TBL] [Abstract][Full Text] [Related]
8. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
[TBL] [Abstract][Full Text] [Related]
9. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications.
Khanna AK; Plummer MS; Hilton G; Pieper GM; Ledbetter S
Circulation; 2004 Dec; 110(25):3822-9. PubMed ID: 15583082
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Feria I; Pichardo I; Juárez P; Ramírez V; González MA; Uribe N; García-Torres R; López-Casillas F; Gamba G; Bobadilla NA
Kidney Int; 2003 Jan; 63(1):43-52. PubMed ID: 12472767
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Andoh TF
Am J Transplant; 2002 Feb; 2(2):111-9. PubMed ID: 12099512
[TBL] [Abstract][Full Text] [Related]
12. Analysis of transforming growth factor-beta and profibrogenic molecules in a rat cardiac allograft model treated with cyclosporine.
Khanna AK; Hosenpud JS; Plummer MS; Hosenpud JD
Transplantation; 2002 May; 73(10):1543-9. PubMed ID: 12042638
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Pérez-Rojas J; Blanco JA; Cruz C; Trujillo J; Vaidya VS; Uribe N; Bonventre JV; Gamba G; Bobadilla NA
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F131-9. PubMed ID: 16835406
[TBL] [Abstract][Full Text] [Related]
14. Expression of transforming growth factor-beta-inducible gene-h3 in normal and cyclosporine-treated rat kidney.
Sun BK; Li C; Lim SW; Jung JY; Lee SH; Kim IS; Kim YS; Kim J; Bang BK; Yang CW
J Lab Clin Med; 2004 Mar; 143(3):175-83. PubMed ID: 15007308
[TBL] [Abstract][Full Text] [Related]
15. Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity.
Sánchez-Pozos K; Lee-Montiel F; Pérez-Villalva R; Uribe N; Gamba G; Bazan-Perkins B; Bobadilla NA
Nephrol Dial Transplant; 2010 Jul; 25(7):2150-8. PubMed ID: 20139407
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells.
Waiser J; Dell K; Böhler T; Dogu E; Gaedeke J; Budde K; Neumayer HH
Nephrol Dial Transplant; 2002 Sep; 17(9):1568-77. PubMed ID: 12198207
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Kidney Int; 1997 Sep; 52(3):660-73. PubMed ID: 9291185
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow.
Vieira JM; Noronha IL; Malheiros DM; Burdmann EA
Transplantation; 1999 Dec; 68(11):1746-53. PubMed ID: 10609952
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation.
Cotrim P; de Andrade CR; Martelli-Junior H; Graner E; Sauk JJ; Coletta RD
J Periodontol; 2002 Nov; 73(11):1313-22. PubMed ID: 12479636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
